following a full submission:
galcanezumab (Emgality®) is accepted for restricted use within NHSScotland.
Indication under review: prophylaxis of migraine in adults who have at least 4 migraine days per month.
SMC restriction: for the treatment of patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.
In studies in patients with episodic and chronic migraine, galcanezumab significantly reduced the number of migraine days per month compared with placebo.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
- Medicine name:
- galcanezumab (Emgality)
- SMC ID:
Prophylaxis of migraine in adults who have at least 4 migraine days per month
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 12 April 2021